



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## MC-Val-Cit-PAB-MMAF

|                                                                           |                                                                  |
|---------------------------------------------------------------------------|------------------------------------------------------------------|
| Cat. No.:                                                                 | HY-112786                                                        |
| CAS No.:                                                                  | 863971-17-9                                                      |
| Molecular Formula:                                                        | C <sub>68</sub> H <sub>103</sub> N <sub>11</sub> O <sub>16</sub> |
| Molecular Weight:                                                         | 1330.61                                                          |
| Target:                                                                   | Drug-Linker Conjugates for ADC                                   |
| Pathway:                                                                  | Antibody-drug Conjugate/ADC Related                              |
| Storage:                                                                  | 4°C, stored under nitrogen                                       |
| * The compound is unstable in solutions, freshly prepared is recommended. |                                                                  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (75.15 mM; Need ultrasonic)  
H<sub>2</sub>O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

|                              | Solvent<br>Concentration | Mass | 1 mg      | 5 mg      | 10 mg     |
|------------------------------|--------------------------|------|-----------|-----------|-----------|
|                              |                          |      |           |           |           |
| Preparing<br>Stock Solutions | 1 mM                     |      | 0.7515 mL | 3.7577 mL | 7.5153 mL |
|                              | 5 mM                     |      | 0.1503 mL | 0.7515 mL | 1.5031 mL |
|                              | 10 mM                    |      | 0.0752 mL | 0.3758 mL | 0.7515 mL |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

|                           |                                                                                                                                                                                                                                           |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description               | MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity <sup>[1]</sup> . |
| IC <sub>50</sub> & Target | Auristatin                                                                                                                                                                                                                                |

### CUSTOMER VALIDATION

- J Pharm Sci. 2024 Apr 26:S0022-3549(24)00150-3.
- Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1625-1639.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

---

[1]. Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FR $\alpha$  Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA